世界の抗体薬物複合体（ADC）薬物市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Antibody Drug Conjugate (ADC) Drug Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z0370 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、134ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥546,000 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥819,000 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,092,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査資料では、抗体薬物複合体（ADC）薬物のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（イミュノメディクス技術、イミュノゲン技術、シアトル遺伝学技術、その他）、用途別市場規模（バイオテクノロジー企業、専門がんセンター、バイオ医薬品企業、学術研究所、病院、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・抗体薬物複合体（ADC）薬物の市場動向 ・企業の競争状況、市場シェア ・抗体薬物複合体（ADC）薬物の種類別市場規模（イミュノメディクス技術、イミュノゲン技術、シアトル遺伝学技術、その他） ・抗体薬物複合体（ADC）薬物の用途別市場規模（バイオテクノロジー企業、専門がんセンター、バイオ医薬品企業、学術研究所、病院、その他） ・抗体薬物複合体（ADC）薬物の北米市場規模2016-2027（アメリカ、カナダ） ・抗体薬物複合体（ADC）薬物のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・抗体薬物複合体（ADC）薬物のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・抗体薬物複合体（ADC）薬物の中南米市場規模2016-2027（メキシコ、ブラジル） ・抗体薬物複合体（ADC）薬物の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Oxford Bio Therapeutics、Synthon、Progenics Pharmaceuticals、Bayer HealthCare、Millennium Pharmaceuticals、Pfizer、Concortis Bio therapeutics、Roche Holding AG、Seattle Genetics、Heidelberg Pharma、Mersana Therapeutics、Astellas Pharma/Agensys、AbbVie Inc、Celldex Therapeutics、Immunomedics、Agensys、Genentech、ImmunoGen、Sanofi、Genmab、Amgen、Novartis、Eli Lilly） ・結論

Market Analysis and Insights: Global Antibody Drug Conjugate (ADC) Drug Market
The global Antibody Drug Conjugate (ADC) Drug market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Antibody Drug Conjugate (ADC) Drug market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Antibody Drug Conjugate (ADC) Drug market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Antibody Drug Conjugate (ADC) Drug market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Antibody Drug Conjugate (ADC) Drug market.

Global Antibody Drug Conjugate (ADC) Drug Scope and Market Size
Antibody Drug Conjugate (ADC) Drug market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Antibody Drug Conjugate (ADC) Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
by Technology
Mmunomedics Technology
Immunogen Technology
Seattle Genetics Technology
Others
by Product Type
Kadcyla
Adcertis

Segment by Application
Biotechnology Companies
Specialized Cancer Centers
Biopharmaceutical Companies
Academic Research Institutes
Hospitals
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Oxford Bio Therapeutics
Synthon
Progenics Pharmaceuticals
Bayer HealthCare
Millennium Pharmaceuticals
Pfizer
Concortis Bio therapeutics
Roche Holding AG
Seattle Genetics
Heidelberg Pharma
Mersana Therapeutics
Astellas Pharma/Agensys
AbbVie Inc
Celldex Therapeutics
Immunomedics
Agensys
Genentech
ImmunoGen
Sanofi
Genmab
Amgen

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Antibody Drug Conjugate (ADC) Drug Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Mmunomedics Technology
1.2.3 Immunogen Technology
1.2.4 Seattle Genetics Technology
1.2.5 Others
1.3 Market by Application
1.3.1 Global Antibody Drug Conjugate (ADC) Drug Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Biotechnology Companies
1.3.3 Specialized Cancer Centers
1.3.4 Biopharmaceutical Companies
1.3.5 Academic Research Institutes
1.3.6 Hospitals
1.3.7 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Antibody Drug Conjugate (ADC) Drug Market Perspective (2016-2027)
2.2 Antibody Drug Conjugate (ADC) Drug Growth Trends by Regions
2.2.1 Antibody Drug Conjugate (ADC) Drug Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Antibody Drug Conjugate (ADC) Drug Historic Market Share by Regions (2016-2021)
2.2.3 Antibody Drug Conjugate (ADC) Drug Forecasted Market Size by Regions (2022-2027)
2.3 Antibody Drug Conjugate (ADC) Drug Industry Dynamic
2.3.1 Antibody Drug Conjugate (ADC) Drug Market Trends
2.3.2 Antibody Drug Conjugate (ADC) Drug Market Drivers
2.3.3 Antibody Drug Conjugate (ADC) Drug Market Challenges
2.3.4 Antibody Drug Conjugate (ADC) Drug Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Antibody Drug Conjugate (ADC) Drug Players by Revenue
3.1.1 Global Top Antibody Drug Conjugate (ADC) Drug Players by Revenue (2016-2021)
3.1.2 Global Antibody Drug Conjugate (ADC) Drug Revenue Market Share by Players (2016-2021)
3.2 Global Antibody Drug Conjugate (ADC) Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Antibody Drug Conjugate (ADC) Drug Revenue
3.4 Global Antibody Drug Conjugate (ADC) Drug Market Concentration Ratio
3.4.1 Global Antibody Drug Conjugate (ADC) Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Antibody Drug Conjugate (ADC) Drug Revenue in 2020
3.5 Antibody Drug Conjugate (ADC) Drug Key Players Head office and Area Served
3.6 Key Players Antibody Drug Conjugate (ADC) Drug Product Solution and Service
3.7 Date of Enter into Antibody Drug Conjugate (ADC) Drug Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Antibody Drug Conjugate (ADC) Drug Breakdown Data by Type
4.1 Global Antibody Drug Conjugate (ADC) Drug Historic Market Size by Type (2016-2021)
4.2 Global Antibody Drug Conjugate (ADC) Drug Forecasted Market Size by Type (2022-2027)

5 Antibody Drug Conjugate (ADC) Drug Breakdown Data by Application
5.1 Global Antibody Drug Conjugate (ADC) Drug Historic Market Size by Application (2016-2021)
5.2 Global Antibody Drug Conjugate (ADC) Drug Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Antibody Drug Conjugate (ADC) Drug Market Size (2016-2027)
6.2 North America Antibody Drug Conjugate (ADC) Drug Market Size by Type
6.2.1 North America Antibody Drug Conjugate (ADC) Drug Market Size by Type (2016-2021)
6.2.2 North America Antibody Drug Conjugate (ADC) Drug Market Size by Type (2022-2027)
6.2.3 North America Antibody Drug Conjugate (ADC) Drug Market Size by Type (2016-2027)
6.3 North America Antibody Drug Conjugate (ADC) Drug Market Size by Application
6.3.1 North America Antibody Drug Conjugate (ADC) Drug Market Size by Application (2016-2021)
6.3.2 North America Antibody Drug Conjugate (ADC) Drug Market Size by Application (2022-2027)
6.3.3 North America Antibody Drug Conjugate (ADC) Drug Market Size by Application (2016-2027)
6.4 North America Antibody Drug Conjugate (ADC) Drug Market Size by Country
6.4.1 North America Antibody Drug Conjugate (ADC) Drug Market Size by Country (2016-2021)
6.4.2 North America Antibody Drug Conjugate (ADC) Drug Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Antibody Drug Conjugate (ADC) Drug Market Size (2016-2027)
7.2 Europe Antibody Drug Conjugate (ADC) Drug Market Size by Type
7.2.1 Europe Antibody Drug Conjugate (ADC) Drug Market Size by Type (2016-2021)
7.2.2 Europe Antibody Drug Conjugate (ADC) Drug Market Size by Type (2022-2027)
7.2.3 Europe Antibody Drug Conjugate (ADC) Drug Market Size by Type (2016-2027)
7.3 Europe Antibody Drug Conjugate (ADC) Drug Market Size by Application
7.3.1 Europe Antibody Drug Conjugate (ADC) Drug Market Size by Application (2016-2021)
7.3.2 Europe Antibody Drug Conjugate (ADC) Drug Market Size by Application (2022-2027)
7.3.3 Europe Antibody Drug Conjugate (ADC) Drug Market Size by Application (2016-2027)
7.4 Europe Antibody Drug Conjugate (ADC) Drug Market Size by Country
7.4.1 Europe Antibody Drug Conjugate (ADC) Drug Market Size by Country (2016-2021)
7.4.2 Europe Antibody Drug Conjugate (ADC) Drug Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Antibody Drug Conjugate (ADC) Drug Market Size (2016-2027)
8.2 Asia-Pacific Antibody Drug Conjugate (ADC) Drug Market Size by Type
8.2.1 Asia-Pacific Antibody Drug Conjugate (ADC) Drug Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Antibody Drug Conjugate (ADC) Drug Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Antibody Drug Conjugate (ADC) Drug Market Size by Type (2016-2027)
8.3 Asia-Pacific Antibody Drug Conjugate (ADC) Drug Market Size by Application
8.3.1 Asia-Pacific Antibody Drug Conjugate (ADC) Drug Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Antibody Drug Conjugate (ADC) Drug Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Antibody Drug Conjugate (ADC) Drug Market Size by Application (2016-2027)
8.4 Asia-Pacific Antibody Drug Conjugate (ADC) Drug Market Size by Region
8.4.1 Asia-Pacific Antibody Drug Conjugate (ADC) Drug Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Antibody Drug Conjugate (ADC) Drug Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Antibody Drug Conjugate (ADC) Drug Market Size (2016-2027)
9.2 Latin America Antibody Drug Conjugate (ADC) Drug Market Size by Type
9.2.1 Latin America Antibody Drug Conjugate (ADC) Drug Market Size by Type (2016-2021)
9.2.2 Latin America Antibody Drug Conjugate (ADC) Drug Market Size by Type (2022-2027)
9.2.3 Latin America Antibody Drug Conjugate (ADC) Drug Market Size by Type (2016-2027)
9.3 Latin America Antibody Drug Conjugate (ADC) Drug Market Size by Application
9.3.1 Latin America Antibody Drug Conjugate (ADC) Drug Market Size by Application (2016-2021)
9.3.2 Latin America Antibody Drug Conjugate (ADC) Drug Market Size by Application (2022-2027)
9.3.3 Latin America Antibody Drug Conjugate (ADC) Drug Market Size by Application (2016-2027)
9.4 Latin America Antibody Drug Conjugate (ADC) Drug Market Size by Country
9.4.1 Latin America Antibody Drug Conjugate (ADC) Drug Market Size by Country (2016-2021)
9.4.2 Latin America Antibody Drug Conjugate (ADC) Drug Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Antibody Drug Conjugate (ADC) Drug Market Size (2016-2027)
10.2 Middle East & Africa Antibody Drug Conjugate (ADC) Drug Market Size by Type
10.2.1 Middle East & Africa Antibody Drug Conjugate (ADC) Drug Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Antibody Drug Conjugate (ADC) Drug Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Antibody Drug Conjugate (ADC) Drug Market Size by Type (2016-2027)
10.3 Middle East & Africa Antibody Drug Conjugate (ADC) Drug Market Size by Application
10.3.1 Middle East & Africa Antibody Drug Conjugate (ADC) Drug Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Antibody Drug Conjugate (ADC) Drug Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Antibody Drug Conjugate (ADC) Drug Market Size by Application (2016-2027)
10.4 Middle East & Africa Antibody Drug Conjugate (ADC) Drug Market Size by Country
10.4.1 Middle East & Africa Antibody Drug Conjugate (ADC) Drug Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Antibody Drug Conjugate (ADC) Drug Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Oxford Bio Therapeutics
11.1.1 Oxford Bio Therapeutics Company Details
11.1.2 Oxford Bio Therapeutics Business Overview
11.1.3 Oxford Bio Therapeutics Antibody Drug Conjugate (ADC) Drug Introduction
11.1.4 Oxford Bio Therapeutics Revenue in Antibody Drug Conjugate (ADC) Drug Business (2016-2021)
11.1.5 Oxford Bio Therapeutics Recent Development
11.2 Synthon
11.2.1 Synthon Company Details
11.2.2 Synthon Business Overview
11.2.3 Synthon Antibody Drug Conjugate (ADC) Drug Introduction
11.2.4 Synthon Revenue in Antibody Drug Conjugate (ADC) Drug Business (2016-2021)
11.2.5 Synthon Recent Development
11.3 Progenics Pharmaceuticals
11.3.1 Progenics Pharmaceuticals Company Details
11.3.2 Progenics Pharmaceuticals Business Overview
11.3.3 Progenics Pharmaceuticals Antibody Drug Conjugate (ADC) Drug Introduction
11.3.4 Progenics Pharmaceuticals Revenue in Antibody Drug Conjugate (ADC) Drug Business (2016-2021)
11.3.5 Progenics Pharmaceuticals Recent Development
11.4 Bayer HealthCare
11.4.1 Bayer HealthCare Company Details
11.4.2 Bayer HealthCare Business Overview
11.4.3 Bayer HealthCare Antibody Drug Conjugate (ADC) Drug Introduction
11.4.4 Bayer HealthCare Revenue in Antibody Drug Conjugate (ADC) Drug Business (2016-2021)
11.4.5 Bayer HealthCare Recent Development
11.5 Millennium Pharmaceuticals
11.5.1 Millennium Pharmaceuticals Company Details
11.5.2 Millennium Pharmaceuticals Business Overview
11.5.3 Millennium Pharmaceuticals Antibody Drug Conjugate (ADC) Drug Introduction
11.5.4 Millennium Pharmaceuticals Revenue in Antibody Drug Conjugate (ADC) Drug Business (2016-2021)
11.5.5 Millennium Pharmaceuticals Recent Development
11.6 Pfizer
11.6.1 Pfizer Company Details
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Antibody Drug Conjugate (ADC) Drug Introduction
11.6.4 Pfizer Revenue in Antibody Drug Conjugate (ADC) Drug Business (2016-2021)
11.6.5 Pfizer Recent Development
11.7 Concortis Bio therapeutics
11.7.1 Concortis Bio therapeutics Company Details
11.7.2 Concortis Bio therapeutics Business Overview
11.7.3 Concortis Bio therapeutics Antibody Drug Conjugate (ADC) Drug Introduction
11.7.4 Concortis Bio therapeutics Revenue in Antibody Drug Conjugate (ADC) Drug Business (2016-2021)
11.7.5 Concortis Bio therapeutics Recent Development
11.8 Roche Holding AG
11.8.1 Roche Holding AG Company Details
11.8.2 Roche Holding AG Business Overview
11.8.3 Roche Holding AG Antibody Drug Conjugate (ADC) Drug Introduction
11.8.4 Roche Holding AG Revenue in Antibody Drug Conjugate (ADC) Drug Business (2016-2021)
11.8.5 Roche Holding AG Recent Development
11.9 Seattle Genetics
11.9.1 Seattle Genetics Company Details
11.9.2 Seattle Genetics Business Overview
11.9.3 Seattle Genetics Antibody Drug Conjugate (ADC) Drug Introduction
11.9.4 Seattle Genetics Revenue in Antibody Drug Conjugate (ADC) Drug Business (2016-2021)
11.9.5 Seattle Genetics Recent Development
11.10 Heidelberg Pharma
11.10.1 Heidelberg Pharma Company Details
11.10.2 Heidelberg Pharma Business Overview
11.10.3 Heidelberg Pharma Antibody Drug Conjugate (ADC) Drug Introduction
11.10.4 Heidelberg Pharma Revenue in Antibody Drug Conjugate (ADC) Drug Business (2016-2021)
11.10.5 Heidelberg Pharma Recent Development
11.11 Mersana Therapeutics
11.11.1 Mersana Therapeutics Company Details
11.11.2 Mersana Therapeutics Business Overview
11.11.3 Mersana Therapeutics Antibody Drug Conjugate (ADC) Drug Introduction
11.11.4 Mersana Therapeutics Revenue in Antibody Drug Conjugate (ADC) Drug Business (2016-2021)
11.11.5 Mersana Therapeutics Recent Development
11.12 Astellas Pharma/Agensys
11.12.1 Astellas Pharma/Agensys Company Details
11.12.2 Astellas Pharma/Agensys Business Overview
11.12.3 Astellas Pharma/Agensys Antibody Drug Conjugate (ADC) Drug Introduction
11.12.4 Astellas Pharma/Agensys Revenue in Antibody Drug Conjugate (ADC) Drug Business (2016-2021)
11.12.5 Astellas Pharma/Agensys Recent Development
11.13 AbbVie Inc
11.13.1 AbbVie Inc Company Details
11.13.2 AbbVie Inc Business Overview
11.13.3 AbbVie Inc Antibody Drug Conjugate (ADC) Drug Introduction
11.13.4 AbbVie Inc Revenue in Antibody Drug Conjugate (ADC) Drug Business (2016-2021)
11.13.5 AbbVie Inc Recent Development
11.14 Celldex Therapeutics
11.14.1 Celldex Therapeutics Company Details
11.14.2 Celldex Therapeutics Business Overview
11.14.3 Celldex Therapeutics Antibody Drug Conjugate (ADC) Drug Introduction
11.14.4 Celldex Therapeutics Revenue in Antibody Drug Conjugate (ADC) Drug Business (2016-2021)
11.14.5 Celldex Therapeutics Recent Development
11.15 Immunomedics
11.15.1 Immunomedics Company Details
11.15.2 Immunomedics Business Overview
11.15.3 Immunomedics Antibody Drug Conjugate (ADC) Drug Introduction
11.15.4 Immunomedics Revenue in Antibody Drug Conjugate (ADC) Drug Business (2016-2021)
11.15.5 Immunomedics Recent Development
11.16 Agensys
11.16.1 Agensys Company Details
11.16.2 Agensys Business Overview
11.16.3 Agensys Antibody Drug Conjugate (ADC) Drug Introduction
11.16.4 Agensys Revenue in Antibody Drug Conjugate (ADC) Drug Business (2016-2021)
11.16.5 Agensys Recent Development
11.17 Genentech
11.17.1 Genentech Company Details
11.17.2 Genentech Business Overview
11.17.3 Genentech Antibody Drug Conjugate (ADC) Drug Introduction
11.17.4 Genentech Revenue in Antibody Drug Conjugate (ADC) Drug Business (2016-2021)
11.17.5 Genentech Recent Development
11.18 ImmunoGen
11.18.1 ImmunoGen Company Details
11.18.2 ImmunoGen Business Overview
11.18.3 ImmunoGen Antibody Drug Conjugate (ADC) Drug Introduction
11.18.4 ImmunoGen Revenue in Antibody Drug Conjugate (ADC) Drug Business (2016-2021)
11.18.5 ImmunoGen Recent Development
11.18 Sanofi
.1 Sanofi Company Details
.2 Sanofi Business Overview
.3 Sanofi Antibody Drug Conjugate (ADC) Drug Introduction
.4 Sanofi Revenue in Antibody Drug Conjugate (ADC) Drug Business (2016-2021)
.5 Sanofi Recent Development
11.20 Genmab
11.20.1 Genmab Company Details
11.20.2 Genmab Business Overview
11.20.3 Genmab Antibody Drug Conjugate (ADC) Drug Introduction
11.20.4 Genmab Revenue in Antibody Drug Conjugate (ADC) Drug Business (2016-2021)
11.20.5 Genmab Recent Development
11.21 Amgen
11.21.1 Amgen Company Details
11.21.2 Amgen Business Overview
11.21.3 Amgen Antibody Drug Conjugate (ADC) Drug Introduction
11.21.4 Amgen Revenue in Antibody Drug Conjugate (ADC) Drug Business (2016-2021)
11.21.5 Amgen Recent Development
11.22 Novartis
11.22.1 Novartis Company Details
11.22.2 Novartis Business Overview
11.22.3 Novartis Antibody Drug Conjugate (ADC) Drug Introduction
11.22.4 Novartis Revenue in Antibody Drug Conjugate (ADC) Drug Business (2016-2021)
11.22.5 Novartis Recent Development
11.23 Eli Lilly
11.23.1 Eli Lilly Company Details
11.23.2 Eli Lilly Business Overview
11.23.3 Eli Lilly Antibody Drug Conjugate (ADC) Drug Introduction
11.23.4 Eli Lilly Revenue in Antibody Drug Conjugate (ADC) Drug Business (2016-2021)
11.23.5 Eli Lilly Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Antibody Drug Conjugate (ADC) Drug Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Mmunomedics Technology
Table 3. Key Players of Immunogen Technology
Table 4. Key Players of Seattle Genetics Technology
Table 5. Key Players of Others
Table 6. Global Antibody Drug Conjugate (ADC) Drug Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Antibody Drug Conjugate (ADC) Drug Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Antibody Drug Conjugate (ADC) Drug Market Size by Regions (2016-2021) & (US$ Million)
Table 9. Global Antibody Drug Conjugate (ADC) Drug Market Share by Regions (2016-2021)
Table 10. Global Antibody Drug Conjugate (ADC) Drug Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 11. Global Antibody Drug Conjugate (ADC) Drug Market Share by Regions (2022-2027)
Table 12. Antibody Drug Conjugate (ADC) Drug Market Trends
Table 13. Antibody Drug Conjugate (ADC) Drug Market Drivers
Table 14. Antibody Drug Conjugate (ADC) Drug Market Challenges
Table 15. Antibody Drug Conjugate (ADC) Drug Market Restraints
Table 16. Global Antibody Drug Conjugate (ADC) Drug Revenue by Players (2016-2021) & (US$ Million)
Table 17. Global Antibody Drug Conjugate (ADC) Drug Market Share by Players (2016-2021)
Table 18. Global Top Antibody Drug Conjugate (ADC) Drug Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Antibody Drug Conjugate (ADC) Drug as of 2020)
Table 19. Ranking of Global Top Antibody Drug Conjugate (ADC) Drug Companies by Revenue (US$ Million) in 2020
Table 20. Global 5 Largest Players Market Share by Antibody Drug Conjugate (ADC) Drug Revenue (CR5 and HHI) & (2016-2021)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Antibody Drug Conjugate (ADC) Drug Product Solution and Service
Table 23. Date of Enter into Antibody Drug Conjugate (ADC) Drug Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Antibody Drug Conjugate (ADC) Drug Market Size by Type (2016-2021) (US$ Million)
Table 26. Global Antibody Drug Conjugate (ADC) Drug Revenue Market Share by Type (2016-2021)
Table 27. Global Antibody Drug Conjugate (ADC) Drug Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 28. Global Antibody Drug Conjugate (ADC) Drug Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 29. Global Antibody Drug Conjugate (ADC) Drug Market Size Share by Application (2016-2021) & (US$ Million)
Table 30. Global Antibody Drug Conjugate (ADC) Drug Revenue Market Share by Application (2016-2021)
Table 31. Global Antibody Drug Conjugate (ADC) Drug Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 32. Global Antibody Drug Conjugate (ADC) Drug Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 33. North America Antibody Drug Conjugate (ADC) Drug Market Size by Type (2016-2021) (US$ Million)
Table 34. North America Antibody Drug Conjugate (ADC) Drug Market Size by Type (2022-2027) & (US$ Million)
Table 35. North America Antibody Drug Conjugate (ADC) Drug Market Size by Application (2016-2021) (US$ Million)
Table 36. North America Antibody Drug Conjugate (ADC) Drug Market Size by Application (2022-2027) & (US$ Million)
Table 37. North America Antibody Drug Conjugate (ADC) Drug Market Size by Country (2016-2021) & (US$ Million)
Table 38. North America Antibody Drug Conjugate (ADC) Drug Market Size by Country (2022-2027) & (US$ Million)
Table 39. Europe Antibody Drug Conjugate (ADC) Drug Market Size by Type (2016-2021) (US$ Million)
Table 40. Europe Antibody Drug Conjugate (ADC) Drug Market Size by Type (2022-2027) & (US$ Million)
Table 41. Europe Antibody Drug Conjugate (ADC) Drug Market Size by Application (2016-2021) (US$ Million)
Table 42. Europe Antibody Drug Conjugate (ADC) Drug Market Size by Application (2022-2027) & (US$ Million)
Table 43. Europe Antibody Drug Conjugate (ADC) Drug Market Size by Country (2016-2021) & (US$ Million)
Table 44. Europe Antibody Drug Conjugate (ADC) Drug Market Size by Country (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Antibody Drug Conjugate (ADC) Drug Market Size by Type (2016-2021) (US$ Million)
Table 46. Asia-Pacific Antibody Drug Conjugate (ADC) Drug Market Size by Type (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Antibody Drug Conjugate (ADC) Drug Market Size by Application (2016-2021) (US$ Million)
Table 48. Asia-Pacific Antibody Drug Conjugate (ADC) Drug Market Size by Application (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Antibody Drug Conjugate (ADC) Drug Market Size by Region (2016-2021) & (US$ Million)
Table 50. Asia-Pacific Antibody Drug Conjugate (ADC) Drug Market Size by Region (2022-2027) & (US$ Million)
Table 51. Latin America Antibody Drug Conjugate (ADC) Drug Market Size by Type (2016-2021) (US$ Million)
Table 52. Latin America Antibody Drug Conjugate (ADC) Drug Market Size by Type (2022-2027) & (US$ Million)
Table 53. Latin America Antibody Drug Conjugate (ADC) Drug Market Size by Application (2016-2021) (US$ Million)
Table 54. Latin America Antibody Drug Conjugate (ADC) Drug Market Size by Application (2022-2027) & (US$ Million)
Table 55. Latin America Antibody Drug Conjugate (ADC) Drug Market Size by Country (2016-2021) & (US$ Million)
Table 56. Latin America Antibody Drug Conjugate (ADC) Drug Market Size by Country (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Antibody Drug Conjugate (ADC) Drug Market Size by Type (2016-2021) (US$ Million)
Table 58. Middle East & Africa Antibody Drug Conjugate (ADC) Drug Market Size by Type (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Antibody Drug Conjugate (ADC) Drug Market Size by Application (2016-2021) (US$ Million)
Table 60. Middle East & Africa Antibody Drug Conjugate (ADC) Drug Market Size by Application (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Antibody Drug Conjugate (ADC) Drug Market Size by Country (2016-2021) & (US$ Million)
Table 62. Middle East & Africa Antibody Drug Conjugate (ADC) Drug Market Size by Country (2022-2027) & (US$ Million)
Table 63. Oxford Bio Therapeutics Company Details
Table 64. Oxford Bio Therapeutics Business Overview
Table 65. Oxford Bio Therapeutics Antibody Drug Conjugate (ADC) Drug Product
Table 66. Oxford Bio Therapeutics Revenue in Antibody Drug Conjugate (ADC) Drug Business (2016-2021) & (US$ Million)
Table 67. Oxford Bio Therapeutics Recent Development
Table 68. Synthon Company Details
Table 69. Synthon Business Overview
Table 70. Synthon Antibody Drug Conjugate (ADC) Drug Product
Table 71. Synthon Revenue in Antibody Drug Conjugate (ADC) Drug Business (2016-2021) & (US$ Million)
Table 72. Synthon Recent Development
Table 73. Progenics Pharmaceuticals Company Details
Table 74. Progenics Pharmaceuticals Business Overview
Table 75. Progenics Pharmaceuticals Antibody Drug Conjugate (ADC) Drug Product
Table 76. Progenics Pharmaceuticals Revenue in Antibody Drug Conjugate (ADC) Drug Business (2016-2021) & (US$ Million)
Table 77. Progenics Pharmaceuticals Recent Development
Table 78. Bayer HealthCare Company Details
Table 79. Bayer HealthCare Business Overview
Table 80. Bayer HealthCare Antibody Drug Conjugate (ADC) Drug Product
Table 81. Bayer HealthCare Revenue in Antibody Drug Conjugate (ADC) Drug Business (2016-2021) & (US$ Million)
Table 82. Bayer HealthCare Recent Development
Table 83. Millennium Pharmaceuticals Company Details
Table 84. Millennium Pharmaceuticals Business Overview
Table 85. Millennium Pharmaceuticals Antibody Drug Conjugate (ADC) Drug Product
Table 86. Millennium Pharmaceuticals Revenue in Antibody Drug Conjugate (ADC) Drug Business (2016-2021) & (US$ Million)
Table 87. Millennium Pharmaceuticals Recent Development
Table 88. Pfizer Company Details
Table 89. Pfizer Business Overview
Table 90. Pfizer Antibody Drug Conjugate (ADC) Drug Product
Table 91. Pfizer Revenue in Antibody Drug Conjugate (ADC) Drug Business (2016-2021) & (US$ Million)
Table 92. Pfizer Recent Development
Table 93. Concortis Bio therapeutics Company Details
Table 94. Concortis Bio therapeutics Business Overview
Table 95. Concortis Bio therapeutics Antibody Drug Conjugate (ADC) Drug Product
Table 96. Concortis Bio therapeutics Revenue in Antibody Drug Conjugate (ADC) Drug Business (2016-2021) & (US$ Million)
Table 97. Concortis Bio therapeutics Recent Development
Table 98. Roche Holding AG Company Details
Table 99. Roche Holding AG Business Overview
Table 100. Roche Holding AG Revenue in Antibody Drug Conjugate (ADC) Drug Business (2016-2021) & (US$ Million)
Table 101. Roche Holding AG Recent Development
Table 102. Seattle Genetics Company Details
Table 103. Seattle Genetics Business Overview
Table 104. Seattle Genetics Antibody Drug Conjugate (ADC) Drug Product
Table 105. Seattle Genetics Revenue in Antibody Drug Conjugate (ADC) Drug Business (2016-2021) & (US$ Million)
Table 106. Seattle Genetics Recent Development
Table 107. Heidelberg Pharma Company Details
Table 108. Heidelberg Pharma Business Overview
Table 109. Heidelberg Pharma Antibody Drug Conjugate (ADC) Drug Product
Table 110. Heidelberg Pharma Revenue in Antibody Drug Conjugate (ADC) Drug Business (2016-2021) & (US$ Million)
Table 111. Heidelberg Pharma Recent Development
Table 112. Mersana Therapeutics Company Details
Table 113. Mersana Therapeutics Business Overview
Table 114. Mersana Therapeutics Antibody Drug Conjugate (ADC) Drug Product
Table 115. Mersana Therapeutics Revenue in Antibody Drug Conjugate (ADC) Drug Business (2016-2021) & (US$ Million)
Table 116. Mersana Therapeutics Recent Development
Table 117. Astellas Pharma/Agensys Company Details
Table 118. Astellas Pharma/Agensys Business Overview
Table 119. Astellas Pharma/Agensys Antibody Drug Conjugate (ADC) Drug Product
Table 120. Astellas Pharma/Agensys Revenue in Antibody Drug Conjugate (ADC) Drug Business (2016-2021) & (US$ Million)
Table 121. Astellas Pharma/Agensys Recent Development
Table 122. AbbVie Inc Company Details
Table 123. AbbVie Inc Business Overview
Table 124. AbbVie Inc Antibody Drug Conjugate (ADC) Drug Product
Table 125. AbbVie Inc Revenue in Antibody Drug Conjugate (ADC) Drug Business (2016-2021) & (US$ Million)
Table 126. AbbVie Inc Recent Development
Table 127. Celldex Therapeutics Company Details
Table 128. Celldex Therapeutics Business Overview
Table 129. Celldex Therapeutics Antibody Drug Conjugate (ADC) Drug Product
Table 130. Celldex Therapeutics Revenue in Antibody Drug Conjugate (ADC) Drug Business (2016-2021) & (US$ Million)
Table 131. Celldex Therapeutics Recent Development
Table 132. Immunomedics Company Details
Table 133. Immunomedics Business Overview
Table 134. Immunomedics Antibody Drug Conjugate (ADC) Drug Product
Table 135. Immunomedics Revenue in Antibody Drug Conjugate (ADC) Drug Business (2016-2021) & (US$ Million)
Table 136. Immunomedics Recent Development
Table 137. Agensys Company Details
Table 138. Agensys Business Overview
Table 139. Agensys Antibody Drug Conjugate (ADC) Drug Product
Table 140. Agensys Revenue in Antibody Drug Conjugate (ADC) Drug Business (2016-2021) & (US$ Million)
Table 141. Agensys Recent Development
Table 142. Genentech Company Details
Table 143. Genentech Business Overview
Table 144. Genentech Antibody Drug Conjugate (ADC) Drug Product
Table 145. Genentech Revenue in Antibody Drug Conjugate (ADC) Drug Business (2016-2021) & (US$ Million)
Table 146. Genentech Recent Development
Table 147. ImmunoGen Company Details
Table 148. ImmunoGen Business Overview
Table 149. ImmunoGen Antibody Drug Conjugate (ADC) Drug Product
Table 150. ImmunoGen Revenue in Antibody Drug Conjugate (ADC) Drug Business (2016-2021) & (US$ Million)
Table 151. ImmunoGen Recent Development
Table 152. Sanofi Company Details
Table 153. Sanofi Business Overview
Table 154. Sanofi Antibody Drug Conjugate (ADC) Drug Product
Table 155. Sanofi Revenue in Antibody Drug Conjugate (ADC) Drug Business (2016-2021) & (US$ Million)
Table 156. Sanofi Recent Development
Table 157. Genmab Company Details
Table 158. Genmab Business Overview
Table 159. Genmab Antibody Drug Conjugate (ADC) Drug Product
Table 160. Genmab Revenue in Antibody Drug Conjugate (ADC) Drug Business (2016-2021) & (US$ Million)
Table 161. Genmab Recent Development
Table 162. Amgen Company Details
Table 163. Amgen Business Overview
Table 164. Amgen Antibody Drug Conjugate (ADC) Drug Product
Table 165. Amgen Revenue in Antibody Drug Conjugate (ADC) Drug Business (2016-2021) & (US$ Million)
Table 166. Amgen Recent Development
Table 167. Novartis Company Details
Table 168. Novartis Business Overview
Table 169. Novartis Antibody Drug Conjugate (ADC) Drug Product
Table 170. Novartis Revenue in Antibody Drug Conjugate (ADC) Drug Business (2016-2021) & (US$ Million)
Table 171. Novartis Recent Development
Table 172. Eli Lilly Company Details
Table 173. Eli Lilly Business Overview
Table 174. Eli Lilly Antibody Drug Conjugate (ADC) Drug Product
Table 175. Eli Lilly Revenue in Antibody Drug Conjugate (ADC) Drug Business (2016-2021) & (US$ Million)
Table 176. Eli Lilly Recent Development
Table 177. Research Programs/Design for This Report
Table 178. Key Data Information from Secondary Sources
Table 179. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Antibody Drug Conjugate (ADC) Drug Market Share by Type: 2020 VS 2027
Figure 2. Mmunomedics Technology Features
Figure 3. Immunogen Technology Features
Figure 4. Seattle Genetics Technology Features
Figure 5. Others Features
Figure 6. Global Antibody Drug Conjugate (ADC) Drug Market Share by Application: 2020 VS 2027
Figure 7. Biotechnology Companies Case Studies
Figure 8. Specialized Cancer Centers Case Studies
Figure 9. Biopharmaceutical Companies Case Studies
Figure 10. Academic Research Institutes Case Studies
Figure 11. Hospitals Case Studies
Figure 12. Others Case Studies
Figure 13. Antibody Drug Conjugate (ADC) Drug Report Years Considered
Figure 14. Global Antibody Drug Conjugate (ADC) Drug Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 15. Global Antibody Drug Conjugate (ADC) Drug Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 16. Global Antibody Drug Conjugate (ADC) Drug Market Share by Regions: 2020 VS 2027
Figure 17. Global Antibody Drug Conjugate (ADC) Drug Market Share by Regions (2022-2027)
Figure 18. Global Antibody Drug Conjugate (ADC) Drug Market Share by Players in 2020
Figure 19. Global Top Antibody Drug Conjugate (ADC) Drug Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Antibody Drug Conjugate (ADC) Drug as of 2020
Figure 20. The Top 10 and 5 Players Market Share by Antibody Drug Conjugate (ADC) Drug Revenue in 2020
Figure 21. Global Antibody Drug Conjugate (ADC) Drug Revenue Market Share by Type (2016-2021)
Figure 22. Global Antibody Drug Conjugate (ADC) Drug Revenue Market Share by Type (2022-2027)
Figure 23. North America Antibody Drug Conjugate (ADC) Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. North America Antibody Drug Conjugate (ADC) Drug Market Share by Type (2016-2027)
Figure 25. North America Antibody Drug Conjugate (ADC) Drug Market Share by Application (2016-2027)
Figure 26. North America Antibody Drug Conjugate (ADC) Drug Market Share by Country (2016-2027)
Figure 27. United States Antibody Drug Conjugate (ADC) Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Canada Antibody Drug Conjugate (ADC) Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. Europe Antibody Drug Conjugate (ADC) Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. Europe Antibody Drug Conjugate (ADC) Drug Market Share by Type (2016-2027)
Figure 31. Europe Antibody Drug Conjugate (ADC) Drug Market Share by Application (2016-2027)
Figure 32. Europe Antibody Drug Conjugate (ADC) Drug Market Share by Country (2016-2027)
Figure 33. Germany Antibody Drug Conjugate (ADC) Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. France Antibody Drug Conjugate (ADC) Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. U.K. Antibody Drug Conjugate (ADC) Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Italy Antibody Drug Conjugate (ADC) Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Russia Antibody Drug Conjugate (ADC) Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Nordic Antibody Drug Conjugate (ADC) Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Asia-Pacific Antibody Drug Conjugate (ADC) Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Asia-Pacific Antibody Drug Conjugate (ADC) Drug Market Share by Type (2016-2027)
Figure 41. Asia-Pacific Antibody Drug Conjugate (ADC) Drug Market Share by Application (2016-2027)
Figure 42. Asia-Pacific Antibody Drug Conjugate (ADC) Drug Market Share by Region (2016-2027)
Figure 43. China Antibody Drug Conjugate (ADC) Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Japan Antibody Drug Conjugate (ADC) Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. South Korea Antibody Drug Conjugate (ADC) Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Southeast Asia Antibody Drug Conjugate (ADC) Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. India Antibody Drug Conjugate (ADC) Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Australia Antibody Drug Conjugate (ADC) Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Latin America Antibody Drug Conjugate (ADC) Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Latin America Antibody Drug Conjugate (ADC) Drug Market Share by Type (2016-2027)
Figure 51. Latin America Antibody Drug Conjugate (ADC) Drug Market Share by Application (2016-2027)
Figure 52. Latin America Antibody Drug Conjugate (ADC) Drug Market Share by Country (2016-2027)
Figure 53. Mexico Antibody Drug Conjugate (ADC) Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Brazil Antibody Drug Conjugate (ADC) Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Middle East & Africa Antibody Drug Conjugate (ADC) Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Middle East & Africa Antibody Drug Conjugate (ADC) Drug Market Share by Type (2016-2027)
Figure 57. Middle East & Africa Antibody Drug Conjugate (ADC) Drug Market Share by Application (2016-2027)
Figure 58. Middle East & Africa Antibody Drug Conjugate (ADC) Drug Market Share by Country (2016-2027)
Figure 59. Turkey Antibody Drug Conjugate (ADC) Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. Saudi Arabia Antibody Drug Conjugate (ADC) Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 61. UAE Antibody Drug Conjugate (ADC) Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 62. Oxford Bio Therapeutics Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2016-2021)
Figure 63. Synthon Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2016-2021)
Figure 64. Progenics Pharmaceuticals Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2016-2021)
Figure 65. Bayer HealthCare Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2016-2021)
Figure 66. Millennium Pharmaceuticals Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2016-2021)
Figure 67. Pfizer Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2016-2021)
Figure 68. Concortis Bio therapeutics Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2016-2021)
Figure 69. Roche Holding AG Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2016-2021)
Figure 70. Seattle Genetics Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2016-2021)
Figure 71. Heidelberg Pharma Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2016-2021)
Figure 72. Mersana Therapeutics Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2016-2021)
Figure 73. Astellas Pharma/Agensys Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2016-2021)
Figure 74. AbbVie Inc Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2016-2021)
Figure 75. Celldex Therapeutics Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2016-2021)
Figure 76. Immunomedics Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2016-2021)
Figure 77. Agensys Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2016-2021)
Figure 78. Genentech Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2016-2021)
Figure 79. ImmunoGen Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2016-2021)
Figure 80. Sanofi Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2016-2021)
Figure 81. Genmab Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2016-2021)
Figure 82. Amgen Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2016-2021)
Figure 83. Novartis Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2016-2021)
Figure 84. Eli Lilly Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2016-2021)
Figure 85. Bottom-up and Top-down Approaches for This Report
Figure 86. Data Triangulation
Figure 87. Key Executives Interviewed

---